Sign in Subscribe

Zymeworks & Jazz Pharmaceuticals Stocks Surge on Positive Cancer Trial Results

Zymeworks jumps 31% and Jazz Pharmaceuticals rises 26% after announcing successful Phase 3 trial results for Ziihera cancer treatment targeting stomach and esophageal cancers.

Zymeworks & Jazz Pharmaceuticals Stocks Surge on Positive Cancer Trial Results
"Ziihera (zanidatamab-hrii) Carton and Vial" Credit: Jazz Pharmaceuticals
Already have an account? Sign in.